Glidepath Health Launches to Bring Operational Certainty to Cell and Gene Therapy Delivery - Business Wire

WINNIPEG — Provincial and territorial health ministers are still pushing for clarity on federal funding despite a one-year extension on some programs, Manitoba Health Minister Uzoma Asagwara said Thursday. Speaking as host of the meeting of ministers in Winnipeg, Asagwara said federal confirmation of the extension is a first step but nothing more. “We are unified in stating very clearly that we need to go much further than that,” they said. “We have been asking very consistently for full clarity on all of the bilateral agreements and the Canada Health Transfer, and we remain unified in that ask.”Federal Health Minister Marjorie Michel announced an extension of funding on social media late Wednesday. She said it represents $1.2 billion in funding for mental health, addictions and home care. The existing funding was set to expire next year. The funding doesn’t add any new programming and doesn’t provide the certainty needed to plan long-term, said Ontario Health Minister Sylvia Jones.

WINNIPEG - Provincial and territorial health ministers are still pushing for clarity on federal funding despite a one-year extension on some programs, Manitoba Health Minister Uzoma Asagwara said Thursday.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.